What does tissue reconstruction — operating income (loss) mean?

This measures the profitability of the Tissue Reconstruction segment by subtracting total operating costs from segment revenues. It is the primary metric for assessing the operational performance and financial health of this specific business unit.

Integra LifeSciences IART Tissue Reconstruction — Operating Income (Loss)

Other segment segments

Specialty Surgery

$83.13M—

Similar metrics at other companies

BLCOSurgical — Operating Income (Loss)

$9M+229%

ASSTMedical Device — Operating Income (Loss)

-$6.11M—

UFPIConstruction — Operating Income

$15.36M-44.8%

DNLITherapeutics Segment — Operating Income (Loss)

-$137.36M+5.6%

NHCInpatient Services — Operating Income

$33.05M+1.2%

DHRLife Sciences — Operating Income (Loss)

$225M+11.9%

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's tissue reconstruction — operating income (loss).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's tissue reconstruction — operating income (loss)?: Integra LifeSciences (IART) reported tissue reconstruction — operating income (loss) of $20.27M in Q1 2026.
What does tissue reconstruction — operating income (loss) mean?: This measures the profitability of the Tissue Reconstruction segment by subtracting total operating costs from segment revenues. It is the primary metric for assessing the operational performance and financial health of this specific business unit.